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Aims To determine whether myocardial fibrosis and greyzone fibrosis (GZF) on cardiovascular magnetic resonance
(CMR) is associated with ventricular arrhythmias in patients with coronary artery disease (CAD) and a left ventric-




In this retrospective study of CAD patients, GZF mass using the 3SD method (GZF3SD) and total fibrosis mass us-
ing the 2SD method (TF2SD) on CMR were assessed in relation to the primary, combined endpoint of sudden car-
diac death, ventricular tachycardia, ventricular fibrillation, or resuscitated cardiac arrest. Among 701 patients [age:
65.8 ± 12.3 years (mean ± SD)], 28 (3.99%) patients met the primary endpoint over 5.91 years (median; interquar-
tile range 4.42–7.64). In competing risks analysis, a GZF3SD mass >_5.0 g was strongly associated with the primary
endpoint [subdistribution hazard ratio (sHR): 17.4 (95% confidence interval, CI 6.64–45.5); area under receiver op-
erator characteristic curve (AUC): 0.85, P < 0.001]. A weaker association was observed for TF2SD mass >_23 g [sHR
10.4 (95% CI 4.22–25.8); AUC: 0.80, P < 0.001]. The range of sHRs for GZF3SD mass (1–527) was wider than for
TF2SD mass (1–37.6).
...................................................................................................................................................................................................
Conclusions In CAD patients with an LVEF >35%, GZF3SD mass was strongly associated with the arrhythmic endpoint. These
findings hold promise for its use in identifying patients with CAD and an LVEF >35% at risk of arrhythmic events.
                                                                                                                                                                                                                   
* Corresponding author. Tel: þ44 121 371 2000. E-mail address: cardiologists@hotmail.com
VC The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology..
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com











Keywords Cardiovascular magnetic resonance • Coronary artery disease • Sudden cardiac death • Ventricular
tachycardia • Ventricular fibrillation • Greyzone scar • Myocardial fibrosis
Introduction
Current guidelines recommend implantable cardioverter-defibrilla-
tors (ICDs) for the prevention of sudden cardiac death (SCD) in sur-
vivors of ventricular fibrillation (VF) or sustained ventricular
tachycardia (VT), and for its primary prevention in patients with a left
ventricular ejection fraction (LVEF) <_30% or <_35%, depending on
functional class.1 These cut-offs of LVEF were based on the inclusion
criteria of the core ICD trials rather than on a previous validation of
LVEF as a predictor of ventricular arrhythmias or benefit from ICDs.
Within these cut-offs, there is no doubt that ICDs are effective.
However, most primary prevention ICD recipients selected on the
Graphical Abstract
Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) was used to detect myocardial fibrosis in patients with coronary artery dis-
ease (CAD). As shown in the horizontal long axis (left upper panel) and short-axis views (left lower panel) of the left ventricle, areas of greyzone fibrosis are
typically heterogeneous, often harbouring ‘channels’ in between areas of myocardial fibrosis. As shown in the survival curves (right upper panel), the propor-
tional risk of the primary endpoint increased with increasing greyzone fibrosis mass using the 3SD method (GZF3SD). In comparison to left ventricular ejec-
tion fraction (LVEF) and total fibrosis mass, this risk, expressed in terms of subdistribution hazard ratios (sHRs) from competing risks analyses, was much
higher for GZF3SD than for total fibrosis mass using the 2SD method, or LVEF (right lower panel). LV, left ventricle; RV, right ventricle.
What’s new?
• Greyzone fibrosis mass using the 3SD method (GZF3SD) mass
was more strongly associated with ventricular arrhythmias
than total fibrosis mass using the 2SD method or left
ventricular ejection fraction (LVEF) in coronary artery disease
(CAD) patients with an LVEF >35%.
• Whether or not appropriately selected patients with CAD
and LVEF >35% benefit from implantable cardioverter-
defibrillators should be addressed in randomized, controlled
trials.
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basis of an LVEF <_35% do not receive therapy from the device. On
the other hand, most patients succumbing to SCD have an LVEF
>35%, both after myocardial infarction (MI) and in the general
population.2
Several authorities,2 including the National Heart, Lung and Blood
Institute and Heart Rhythm Society,3 have recognized the inability of
LVEF to predict arrhythmic events and have called for alternative risk
stratification tools. Cardiovascular magnetic resonance (CMR) has
emerged as a promising alternative. Myocardial fibrosis (MF), identi-
fied using late gadolinium enhancement, has been linked to ventricu-
lar arrhythmias in numerous studies.4,5 In addition, the so-called
greyzone fibrosis (GZF), an admixture of MF and viable tissue
thought to be a substrate for ventricular arrhythmias, identifiable
with CMR, has also been shown to be associated with ventricular
arrhythmias in clinical studies.6
The recent Cardiovascular Magnetic Resonance—Sudden Cardiac
Death (CMR-SCD) study, which included patients with coronary ar-
tery disease (CAD) and a wide range of LVEFs, showed that GZF was
as a strong predictor of SCD and a composite, arrhythmic endpoint
of SCD, resuscitated cardiac arrest, VF or VT.7 It also showed that
49% of SCDs occurred in patients with an LVEF >35%. The present
subanalysis of the CMR-SCD study explores whether MF and GZF
are associated with arrhythmic events in patients with CAD and an
LVEF >35%.
Methods
This is a subanalysis of the Cardiovascular Magnetic Resonance for the
prediction of Sudden Cardiac Death (CMR-SCD) study,7 a retrospective
study of patients from a single centre (University Hospitals Birmingham,
Queen Elizabeth, UK) referred for a CMR scan from July 2010 to August
2017. Approval was obtained from local Ethical Committee and the hos-
pital’s Clinical Audit Department, both of which waived the need for pa-
tient consent for retrospectively acquired data. The study conforms with
the Declaration of Helsinki.
In the CMR-SCD study,7 clinical documentation and CMR reports
were retrospectively screened to determine whether patients satisfied in-
clusion and exclusion criteria. Inclusion criteria were: CAD, defined as: (i)
previous MI, percutaneous coronary intervention or coronary artery by-
pass grafting; or (ii) coronary angiography showing >_70% stenosis in >_1
coronary artery or >_50% stenosis of the left main stem; or (iii) MF on
CMR in an ischaemic distribution; and (iv) LVEF >35% for the purposes of
the present subanalysis. Exclusion criteria were as follows: congenital
heart disease or adult cardiac disease other than CAD, including valvular
disease and channelopathies; a previous cardiac arrest or episode of VT
or VF outside the context of a MI; a cardiac implantable electronic device
implanted prior to the CMR scan, excluding implantable loop recorders;
incomplete follow-up, defined as inability to corroborate from clinical
records whether complete information on clinical events was available in
our centre or referring centres. Patients who had a cardiac implantable
electronic device after the CMR scan were not excluded.
Cardiovascular magnetic resonance
A 1.5 Tesla scanner (MAGNETOM Symphony or Avanto: Siemens,
Erlangen, Germany) and a phased array cardiac coil, were used as previ-
ously described.7 Late gadolinium enhancement CMR were acquired as
short-axis slices and a segmented inversion-recovery sequence 10 min af-
ter the intravenous administration of gadolinium contrast (MagnevistVR or
GadovistVR at 0.15–0.2 mmol/kg). Myocardial fibrosis was quantified using
CMR42 software (Circle Cardiovascular Imaging, Calgary, Canada) by an
investigator who was blinded to patient outcomes.
The signal threshold vs. reference myocardium technique was used to
quantify to quantify total fibrosis mass using the 2SD method (TF2SD) and
GZF mass using the 3SD method (GFZ3SD). To this end, remote, nulled
myocardium was identified manually as reference. Total fibrosis mass was
quantified using a semiautomatic detection algorithm and defined in terms
of signal-intensity thresholds above reference myocardium. In the CMR-
SCD, GZF3SD was the most consistent measure in predicting SCD and ar-
rhythmic events.7 The difference between TF2SD and the TF using the
3SD method8 constitutes GZF3SD. Both TF2SD and GZF3SD were
expressed in grams by multiplying enhanced area by slice thickness.
Volume was converted to mass using the myocardial specific gravity of
1.055 g/mL.
Endpoints
The primary endpoint was the composite arrhythmic endpoint of SCD,
resuscitated cardiac arrest, sustained VT or VF, or appropriate ICD
shock. A ventricular rhythm faster than 100 b.p.m. lasting at least 30 s or
requiring termination due to hemodynamic instability, by antitachycardia
pacing or shocks was regarded as sustained VT. In patients with defibrilla-
tion devices, electrograms were reviewed to determine arrhythmias and
to decide whether delivered shocks were appropriate or inappropriate.
Only appropriate shocks were considered in the arrhythmic endpoint. In
patients without devices, ECG documentation of arrhythmias was re-
quired. Reports of an arrhythmia without ECG documentation were dis-
counted. The ancillary endpoint was total mortality. Investigators who
were blinded to clinical and imaging data collected clinical outcome data
every 6 months from medical records. Event adjudication was undertaken
by the investigators 6-monthly, up to May 2020. A national health tracking
system that provides vital status data to all hospitals in the UK (SPINE
Portal) was used to check survival status. Causes of death were adjudi-
cated on the basis of hospital records and correspondence from primary
care physicians. Deaths were classified as unknown if no definitive data
was found in hospital or primary care records.
A SCD was defined as a natural, unexpected death due to cardiac
causes, heralded by an abrupt loss of consciousness within one hour of
the onset of acute symptoms.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation (SD).
Normality was tested using the Shapiro–Wilk test. Cumulative incidence
curves were used to assess cumulative survival. Cox proportional hazard
models were used to assess relative risks. In analyses where the compara-
tor had zero events and the partial likelihood converged to a finite value,
Firth’s penalized partial likelihood correction was applied to Cox regres-
sion models.9 Fine and Gray proportional subdistribution hazard mod-
els10 and the cumulative incidence function were used in competing risks
analyses. Death other than SCD and without ventricular arrhythmias was
used in competing risk in analyses of the primary endpoint, the first event
was used for censoring.
In exploratory analyses, all patients who met the primary endpoint had
MF on visual assessment. Absolute mass for both TF2SD and GZF3SD was
used in statistical analyses. For the assessment of MF, TF2SD and GZF3SD
mass were imputed as zero if there was no MF on visual assessment. In all
models, absolute mass was entered as continuous and dichotomous vari-
ables, and the latter were defined empirically using the optimal cut-offs as-
sociated with the Youden index in receiver operating characteristic
analyses, bootstrapped (500 replications) to estimate confidence intervals
(CIs). Differences between areas under the receiver operator
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characteristic curves (AUCs) were assessed using De Long’s test.
Variables which achieved a P < 0.10 on univariate analyses for the primary
endpoint were included in multivariable models. Statistical analyses were
undertaken using Stata15 (StataCorp, Texas; ‘stcrreg’ for Fine and Gray
models). The R package (The R Foundation for Statistical Computing,
Vienna) ‘coxphf’ (run on R version 3.6.5) was used for Firth’s penalized
partial likelihood correction.
Results
The derivation of the CMR-SCD study cohort has been previously
described.7 Our focus in the present subanalysis were the 701
patients with an LVEF >35% from the original cohort of 979. As
shown in Table 1, patients who met the primary endpoint were more
likely to have had a MI (P = 0.001) and obstructed coronary arteries
on angiography (P = 0.025). In addition, they had higher left ventricu-
lar end-systolic and end-diastolic volumes (both P = 0.001), a lower
LVEF, a higher TF2SD mass and a higher GZF3SD mass (both
P < 0.001).
All patients had complete follow-up until May 2020. Over a
follow-up period of 5.91 years (median; interquartile range 4.42–
7.64), 181 (25.8%) patients died, 119 (17.0%) from known causes and
62 (8.84%) from unknown causes. No patient underwent cardiac
transplantation or left ventricular assist device implantation. A total
of 28 (3.99%) patients met the primary endpoint. The first event
....................................................................................................................................................................................................................
Table 1 Baseline characteristics
All Events No Events P-value
N 701 28 673
Age, years 65 ± 12.4 66.4 ± 11.8 64.9 ± 12.5 0.539
Sex (male) 517 (73.8) 24 (85.7) 493 (73.3) 0.142
Previous cardiac events, n (%)
Myocardial infarction 411 (59.4) 25 (89.3) 386 (57.4) 0.001
Percutaneous coronary intervention 224 (32.4) 11 (39.3) 213 (31.7) 0.396
Coronary artery bypass 133 (18.9) 9 (32.1) 124 (18.4) 0.070
Co-morbidities, n (%)
Diabetes mellitus 118 (17.0) 6 (21.4) 112 (16.6) 0.507
Hypertension 187 (26.9) 8 (28.6) 179 (26.6) 0.817
Coronary angiography
Obstructed coronary arteries 490 (69.9) 26 (92.9) 464 (68.9) 0.025
Unobstructed coronary arteries 70 (9.99) 1 (3.57) 69 (10.3)
Not done 141 (20.1) 1 (3.57) 140 (20.8)
LV CMR volumetric variables
Absolute
LVEDV, mL 151.9 ± 51.6 206.1 ± 56.9 149.7 ± 50.2 <0.001
LVESV, mL 72.7 ± 39.8 113.3 ± 44.3 71.1 ± 38.7 <0.001
LV mass, g 137.4 ± 44.5 160.2 ± 61.8 136.5 ± 43.4 0.006
LVEF, % 54.6 ± 13.4 46.8 ± 9.7 54.9 ± 13.4 0.002
Indexed
LVEDVi, mL/m2 78.2 ± 26.2 98.7 ± 23.4 77.4 ± 25.9 <0.001
LVESVi, mL/m2 37.5 ± 20.6 54.9 ± 20.1 36.8 ± 20.3 <0.001
LV mass, g/m2 72.1 ± 20.5 79.6 ± 23.9 71.8 ± 20.3 0.049
LV CMR fibrosis variables
TF2SD mass, g 15.4 ± 17.3 34 ± 19.6 14.7 ± 16.8 <0.001
GZF3SD mass, g 2.92 ± 2.66 6.9 ± 3.3 2.76 ± 2.5 <0.001
Myocardial fibrosis pattern, n (%)
Present 572 (81.6) 28 (100) 544 (80.8) 0.010
Transmural 357 (50.9) 21 (75) 336 (49.9) 0.009
Subendocardial 204 (29.1) 6 (21.4) 198 (29.4) 0.362
Mixed 9 (1.28) 1 (3.57) 8 (1.19) 0.272
Focal 2 (0.29) 0 2 (0.3) 0.773
CMR, cardiovascular magnetic resonance; GZF3SD, greyzone fibrosis using the 3SD method; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEDVi, left ven-
tricular end-diastolic volume indexed to body surface area; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVESVi,= left ventricular end-sys-
tolic volume indexed to body surface area; TS2SD, total fibrosis mass using the 2 SD method.
Variables are mean ± standard deviation or n (%).
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within this composite endpoint was SCD in 13 (1.85%) and ventricu-
lar arrhythmias in 15 (2.14%) (Table 2).
Greyzone fibrosis
In receiver-operating characteristic analyses, the AUC for GZF3SD
(0.85) with respect to the arrhythmic endpoint was higher than for
total fibrosis (0.80) or LVEF (0.68) (Figure 1). For the primary end-
point, a GZF3SD mass >_5.0 g was associated with a positive predictive
value of 14.4% and a negative predictive value of 99.1%. For SCD, a
GZF3SD mass >_5.0 g was associated with a positive predictive value
of 6.88% and a negative predictive value of 99.6%.
When death other than SCD and no ventricular arrhythmias was
adopted as a competing risk in univariate analyses, GZF3SD mass (per
g) was strongly associated with the arrhythmic endpoint [subdistribu-
tion hazard ratio (sHR): 1.52, 95% CI 1.37–1.70] (Table 3): compared
to GZF3SD <5.0 g, a GZF3SD mass >_5.0 g was associated with a higher
risk of the primary endpoint [hazard ratio (HR) of 17.4 (95% CI 6.64–
45.5)] (Figure 2A). As shown in Figure 3A, the range of predicted sHRs
for GZF3SD mass was considerably wider than for TF2SD mass, from 1
to 526.6
In multivariable analyses, GZF3SD mass (per g) predicted the pri-
mary endpoint (adjusted HR 1.48; 95% CI 1.32–1.67) after adjust-
ment for a history of MI or coronary artery bypass. (Table 3 and
Supplementary material online, Table S2).
In both univariate (HR 1.07, 95% CI 1.02–1.03) and multivariable
(adjusted HR 1.08, 95% CI 1.02–1.14) analyses adopting age and sex
as covariates, GZF3SD mass emerged as predictor of total mortality
(Table 3 and Supplementary material online, Table S3). As shown in
Table 4, GZF3SD mass (adjusted HR 1.57; 95% CI 1.38–1.80) was the
strongest predictor of the primary endpoint when TF2SD mass and
LVEF were included as covariates.
Total fibrosis burden
When death other than SCD and no ventricular arrhythmias was
adopted as a competing risk in univariate analyses, TF2SD mass (per g)
was strongly associated with the primary endpoint (sHR: 1.04, 95%
CI 1.03–1.06) (Table 3): compared to TF2SD mass <23.0 g, a TF2SD
mass >_23.0 g was associated with a higher risk (HR 10.4, 95% CI
4.22–25.8) (Figure 2B). As shown in Figure 3B, predicted sHRs for
TF2SD mass ranged from 1 to 37.6.
In multivariable analyses, TF2SD mass predicted the primary end-
point (HR 1.04, 95% CI 1.32–1.67), after adjustment for a history of
MI or coronary artery bypass (Table 3 and Supplementary material
online, Table S2).
In contrast to GZF3SD, TF2SD failed to emerge as a predictor of to-
tal mortality in univariate or multivariable analyses (Table 3 and
Supplementary material online, Table S3).
Myocardial fibrosis on visual assessment
All patients who met the primary endpoint had MF on visual assess-
ment. In Cox univariable analyses with bias correction for zero
events in the group without MF on visual assessment, MF on visual as-
sessment was strongly associated with the primary endpoint (HR
12.3, 95% CI 1.74–1563, P = 0.005) (Figure 2C).
Left ventricular ejection fraction
As shown in Table 3, LVEF was associated with the primary endpoint
in both univariate (sHR: 0.95, 95% CI 0.92–0.98) and multivariable
(adjusted sHR: 0.95, 95% CI 0.92–0.98) analyses. The distribution of
predicted sHRs for LVEF against the primary endpoint is shown in





Sudden cardiac death, ventricular
tachycardia/fibrillation
28 (3.99)
Sudden cardiac death 13 (1.85)
Ventricular tachycardia/ventricular fibrillation 15 (2.14)
Ancillary endpoint
Total mortality 181 (25.8)
Variables are expressed as n (%).
Figure 1 Receiver operator characteristic curves. Graph shows
receiver operator characteristic curves for LVEF and myocardial fi-
brosis measures as predictors of the primary endpoint. *P = 0.008
for comparison between total fibrosis mass using the 2SD method
(TF2SD) and LVEF. **P < 0.001 for comparison between greyzone fi-
brosis using the 3 SD method (GZF3SD) and LVEF; P = 0.034 for
comparison between GZF3SD and TF2SD. Differences were assessed
using De Long’s test. AUC, area under curve; LVEF, left ventricular
ejection fraction.
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univariate (HR 0.97, 95% CI 0.96–0.98) and multivariable analyses
(adjusted HR 0.98, 95% CI 0.97–0.99) (Table 3 and Supplementary
material online, Table S2).
In a subanalysis of patients with an LVEF >_50% (n = 403), 10
patients met the primary endpoint (SCD in 4, VT in 2 and VF in 2). As
shown in Supplementary material online, Table S4, GZF3SD mass pre-
dicted the primary endpoint on univariate analyses (HR 1.51, 95% CI
1.35–1.68). A weaker association was observed for LVEF (HR 0.90;
95% CI 0.82–0.99).
Correlations
As expected, GZF3SD correlated strongly with TF2SD (r = 0.83,
P < 0.001) (Supplementary material online, Table S5).
Discussion
This is the first study to explore GZF in relation to SCD and ventricu-
lar arrhythmias in CAD patients with an LVEF >35%,11 who currently
fall outside clinical guideline indications for primary prevention ICD
therapy. Several findings have emerged. First, a relatively low propor-
tion (3.99%) met the primary arrhythmic endpoint. Second, all
patients succumbing to the primary endpoint had MF on visual assess-
ment. Third, GZF3SD mass was more strongly associated with the pri-
mary endpoint than TF2SD mass or LVEF. Last, a GZF3SD mass <5 g,
almost excluded a risk of the primary endpoint.
Left ventricular ejection fraction
Currently, primary prevention ICDs are indicated in patients with an
LVEF <_35% or <_30%, in line with the inclusion criteria of the ICD tri-
als. No trial, however, has explored primary prevention ICDs in
patients with LVEF >35%. In this context, we should consider that in
the general population, most individuals succumbing to SCD have an
LVEF >35%. In the Oregon Sudden Unexpected Death Study, cover-
ing a population of 660 486 individuals, the retrospectively assessed
LVEF before SCD was <_35% in 30%, between 36% and 54% in 22%
and >_55% in 48%.2 In other words, 70% of individuals succumbing to
SCD in the general population had an LVEF >35%.
On this basis, we may ask whether increasing the cut-off of LVEF
could capture more patients at risk of SCD and ventricular arrhyth-
mias. However, LVEF is a poor predictor of SCD and arrhythmic
events. Even in ICD recipients with an LVEF <_35%, the minority re-
ceive therapy from the device. In a study of 1729 ICD recipients, the
12-year cumulative incidence were 36% for appropriate therapy.12 In
the Detect Long-term Complications after ICD Replacement
(DECODE) registry of 332 recipients of cardiac resynchronization
with defibrillation devices (primary and secondary prevention; 52%
with ischaemic cardiomyopathy), appropriate ICD therapy had oc-
curred in 37% by the time of device replacement.13 In a study of 1151
patients, 68% of whom had ischaemic cardiomyopathy, a first appro-
priate shock was observed in 23% patients after a mean follow-up of
4.0 years.14 Together, these findings illustrate that a minority of ICD
recipients, even with an LVEF <_35%, do not receive therapy from the
implanted ICD. Given the low event rate in patients with an LVEF
>35%, simply raising the cut-off of LVEF to capture patients at risk is
likely to lead to overtreatment. A parameter other than LVEF would
be desirable in patient selection.
Greyzone fibrosis
The early demonstration that GZF provides a substrate for ventricu-
lar arrhythmias15 has been corroborated by numerous studies. Using
CMR and electroanatomic mapping in patients undergoing VT abla-
tion, Piers et al. showed that critical VT isthmus sites in CAD patients
are typically located in close proximity to the transition zone be-
tween ‘borderzone’, or greyzone, and transmural scars on CMR.16
The correlation between critical VT isthmus sites and CMR-derived
borderzone channels through dense scar areas have also been shown
by others.17 Together, these findings suggest that GZF detected on
CMR denotes a critical mix between fibrosis and viable myocytes
that promotes slow conduction and re-entrant VT. Several small
....................................................................... ........................................................................
....................................................................................................................................................................................................................
Table 3 Univariate and multivariable analyses
Univariate analyses Multivariable analyses
sHR 95% CI P-value sHR 95% CI P-value
Primary endpoint
MF presencea 12.3 1.74–1563 0.005 10.3 1.44–1305 0.013
TF2SD mass, per g 1.04 1.03–1.06 <0.001 1.04 1.03–10.6 <0.001
GZF3SD mass, per g 1.52 1.37–1.70 <0.001 1.48 1.32–1.67 <0.001
LVEF, per % 0.95 0.92–0.98 <0.001 0.95 0.92–0.98 0.003
Total mortality
MF presence 1.35 0.89–2.04 0.161 1.19 0.78–1.81 0.412
TF2SD mass, per g 1.01 1.00–1.01 0.108 1.01 1.00–1.02 0.060
GZF3SD mass, per g 1.07 1.02–1.03 0.006 1.08 1.02–1.14 0.007
LVEF, per % 0.97 0.96–0.98 <0.001 0.98 0.97–0.99 <0.001
Results from competing risks analyses with respect to the primary are expressed in terms of subdistribution hazard ratios (sHRs) and 95% confidence intervals (95% CIs).
Results for total mortality were derived from Cox proportional hazards models, without correction for competing risks. Detailed results of the multivariable models are shown
in Supplementary material online, Tables S2 and S3.
GZF3SD, greyzone fibrosis using the 3SD method; LVEF, left ventricular ejection fraction; MF, myocardial fibrosis; TF2SD, total fibrosis using the 2 SD method.
aFrom Firth’s penalized likelihood method.
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studies6,18–20 have indeed supported a link between GZF and ar-
rhythmic events. Importantly, however, these studies mainly included
patients with an LVEF <_35% implanted with an ICD. The novel finding
from the present study is that the association between GZF and
ventricular arrhythmias also applies to CAD patients with an LVEF
>35%.
In the CMR-SCD study, neither TF2SD mass or GZF3SD mass were
associated with total mortality, whereas significant associations were
observed in the present subanalysis. A possible explanation is that
the original cohort of the CMR-SCD study also included patients
with an LVEF <_35% who are at a higher risk of death from other
Figure 2 Events according to myocardial fibrosis measures.
Cumulative hazards estimates from competing risks analyses for the
arrhythmic endpoint, expressed in terms of subdistribution hazard
ratios (sHRs) and 95% confidence intervals (CIs). Patients were di-
chotomized according to (A) greyzone fibrosis mass quantified using
the 3SD method (GZF3SD); (B) total fibrosis mass using the 2 SD
method (TF2SD); and, (C) presence (MFVA) or absence of myocardial
fibrosis on visual assessment. In (C) competing risks analyses were
not undertaken for MFVA, given zero events in the comparator
group.
Figure 3 Comparative risks of myocardial fibrosis measures and
LVEF. Cubic splines (with 3 knots) showing predicted subdistribu-
tion hazard ratios (sSHR) from competing risks analyses for grey-
zone mass using the 3SD method (GZF3SD), total fibrosis mass
using the 2 SD method (TF2SD) and LVEF in relation to the primary
end point. Reference values were: 0 g for GZF3SD and TF2SD and
35% for LVEF. LVEF, left ventricular ejection fraction.
.................................................................................................
Table 4 Multivariable analyses: comparison between
total fibrosis, greyzone fibrosis, and LVEF
sHR 95% CI P-value
Primary endpoint
TF2SD mass, per g 0.99 0.97–1.02 0.486
GZF3SD mass, per g 1.57 1.38–1.80 <0.001
LVEF, per % 0.99 0.95–1.03 0.558
Total mortality
MF presence 0.91 0.57–1.48 0.716
TF2SD mass, per g 0.99 0.97–1.00 0.055
GZF3SD mass, per g 1.09 0.99–1.21 0.066
LVEF, per % 0.97 0.96–0.98 <0.001
Results from competing risks analyses with respect to the primary are expressed
in terms of subdistribution hazard ratios (sHRs) and 95% confidence intervals
(95% CIs).
GZF3SD, greyzone fibrosis using the 3SD method; LVEF, left ventricular ejection
fraction; MF, myocardial fibrosis; TF2SD, total fibrosis using the 2 SD method.
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competing causes, such as heart failure. It is possible, therefore, that
the relationship between GZF3SD and total mortality is ‘diluted’ by a
low LVEF.
Total fibrosis
Whilst GZF may act as the substrate for VT re-entry circuits, areas of
dense MF are also required to create the isthmus. In imaging terms,
both GZF and dense MF are required for arrhythmogenesis. It is
therefore not surprising that MF, visually assessed and without dis-
tinction of GZF from dense scar, predicts arrhythmic events. In this
respect, multiple meta-analyses of studies in patients with CAD or
non-ischaemic cardiomyopathy points towards an association be-
tween the presence of MF on visual assessment and arrhythmic
events.5 These findings are supported by the present study, in which
all patients meeting the primary endpoint had MF on visual assess-
ment. Moreover, we observed a graded strength of the association
between increasing TF2SD mass and arrhythmic events.
Clinical application
The patient population included herein is not currently indicated for
primary prevention ICDs. Our findings should not be interpreted as
justification for using ICDs in patients with an LVEF >35% and a high
GZF3SD mass, as we have only addressed arrhythmic events, rather
than ‘benefit’ from ICD therapy. Although the event rate was rela-
tively low, a high GZF3SD mass has the potential for the identification
of CAD patients with an LVEF >35% at risk of arrhythmic events.
Speculatively, one could propose offering ICDs to patients with an
LVEF >35% and a GZF3SD >_5 g. In our cohort, this would potentially
apply to 160/701 (23%) of CAD patients with an LVEF >35%, which
would amount to a substantial increase in ICD implantation beyond
current guidelines. However, with reference to all patients included
in the CMR-SCD study,7 selecting patients on the basis of a GZF3SD
>_5 g alone, would also reduce potential ICD implantations in the
LVEF <_35% population. Whilst, overall, prescription of ICDs would
increase using this strategy, there would be less overtreatment of
patients with an LVEF <_35% and less undertreatment in those with
an LVEF >35%. Conversely, one could use the negative predictive
value of GZF3SD >_5 g, which in this study was 99.1% for the primary
endpoint and 99.6% for SCD. On this basis, one could be reasonably
certain that if GZF is <5 g, the risk of an arrhythmic event is ex-
tremely low.
Limitations
Prominent amongst the limitations of the present study is its retro-
spective nature. However, it reflects ‘real-world’ clinical practice dur-
ing long-term follow-up. Importantly, this study included patients
with complex CAD referred to a tertiary CMR centre, an aspect
which may account for the relatively high event rate. Its findings,
therefore, may not be generalizable to other populations, particularly
asymptomatic patients. Unfortunately, we have no data on New
York Heart Association class, atrial rhythm or renal function, all of
which are relevant to ventricular arrhythmias and their competing
risks. We cannot discount the possibility that these variables may be
relevant to arrhythmic risk stratification, either alone or in combina-
tion. The absence of these data also precludes comparisons with sim-
ilar patient cohorts. Clinical application of our findings will require
external validation in prospective studies, ideally using an
independent endpoint committee. The number of deaths from un-
known causes (n = 62) could influence the results, despite competing
risks analyses. We have not compared the CMR variables included
herein with the numerous other parameters that are known to be of
value in arrhythmic risk stratification.3 However, the strength of the
observed associations would appear to be on a much higher scale
than those observed for other parameters. The study was under-
powered for SCD and therefore, we cannot comment on GZF3SD in
relation to SCD per se.
Conclusions
In CAD patients with an LVEF >35%, GZF3SD mass was more
strongly associated with the primary, arrhythmic endpoint than LVEF
or TF2SD mass. These findings are consistent with the observation
that GZF is a substrate for ventricular arrhythmias. On this basis,
quantification of GZF3SD mass has the potential for identifying
patients with CAD and an LVEF >35% at risk of arrhythmic events
and, possibly, those who may benefit from ICD therapy.
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